器官损伤蛋白质组学特征识别有系统性并发症风险的代谢功能障碍相关脂肪性肝病患者
该研究结合多维组学方法,利用92重靶向循环蛋白质组 panel 在60,042名个体中探索追踪系统性器官损伤的可行性,发现ADGRG1(GPR56)等蛋白在进展性疾病和显著纤维化风险患者中失调,ADGRG1与16年随访中终末期肝病、死亡、慢性阻塞性肺疾病和缺血性心脏病风险相关。
要点
- ADGRG1(GPR56)等蛋白在进展性MASLD和显著纤维化风险患者中失调。
- ADGRG1与16年随访中终末期肝病、死亡、COPD和缺血性心脏病风险相关。
- ADGRG1肝脏表达与循环模式一致,损伤时在纤维化和炎症微环境细胞中上调。
核心结论
- 研究提供了一种与系统性疾病相关潜在机制的框架,通过将MASLD患者分层为有肝外表现风险的亚类,促进整体管理。
研究设计与样本
- 研究采用多维组学方法,使用92重优先蛋白质 panel 对患者血清进行深度表型分析,纳入发现和复制阶段共60,042名个体的蛋白质组数据,使用多种研究设计和交叉蛋白质组平台,并利用肝脏类器官数据评估细胞类型特异性转录变化。
主要发现
- ADGRG1等 implicated 蛋白在进展性疾病和显著纤维化风险患者中失调。
- ADGRG1被验证为器官损伤的替代标志物,与16年随访中终末期肝病风险增加、中等但临床显著的死亡风险、慢性阻塞性肺疾病和缺血性心脏病相关, regardless of MASLD状态。
- ADGRG1肝脏表达与循环模式一致。
- 机制研究表明,损伤反应中ADGRG1在纤维化和炎症微环境细胞中转录谱从低表达转为上调。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease affects more than 30% of the world's population and is associated with multisystemic comorbidities. We combined multidimensional OMICs approaches to explore the feasibility of using high-throughput targeted circulating proteomics to track systemic organ damage and infer the underlying molecular mechanisms. APPROACH AND RESULTS: We evaluated a 92-plex panel of prioritized proteins with pathophysiological relevance to organ damage in serum samples of patients using in-depth phenotyping. We included proteomic data from 60,042 individuals in the discovery and replication stages using diverse study designs and cross-proteomic platforms. We used deconvolution strategies to investigate whether the affected liver participated in the expression of biomarkers of organ damage. To assess cell type-specific transcriptional changes in the selected target, we used liver organoid data. The implicated proteins, including ADGRG1 (GPR56), are deregulated in patients who are at risk of progressive disease and significant fibrosis. ADGRG1 was validated as a surrogate for organ damage, as it was associated with increased risk of end-stage liver disease, moderate but clinically significant risk of death, chronic obstructive pulmonary disease, and ischemic heart disease over a 16-year follow-up, regardless of the subject's metabolic dysfunction-associated steatotic liver disease status. ADGRG1 liver expression mirrors the circulation pattern. Mechanistic insights show that ADGRG1 shifts its transcriptional profile from low expression to upregulation in cells of the fibrotic and inflammatory niche in response to injury. CONCLUSIONS: Our study provides a framework for potential mechanisms associated with systemic diseases that facilitates holistic management by stratifying patients with metabolic dysfunction-associated steatotic liver disease into subclasses at risk of extrahepatic manifestations.
引用
- Pirola CJ, Diambra L, Fernández Gianotti T, et al. Organ damage proteomic signature identifies patients with MASLD at risk of systemic complications. Hepatology. 2025. PMID: 40310655. doi:10.1097/HEP.0000000000001346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。